2007
Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients
Sun A, Yu T, Wang L, Lu J, Gonzales G, Pusztai L, Singletary S, Ross M, Wei Q, Buchholz T. Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients. Journal Of Clinical Oncology 2007, 25: 574-574. DOI: 10.1200/jco.2007.25.18_suppl.574.Peer-Reviewed Original ResearchBreast cancer patientsAbsolute neutrophil countChemotherapy-induced neutropenic feverNeutropenic feverCancer patientsC polymorphismChemotherapy-induced bone marrow toxicityGene polymorphismsMultivariable logistical regression analysisMultivariable logistic regression modelGrowth factor supportPolymerase chain reaction-restriction fragment length polymorphism methodBone marrow toxicityTwo-sided ChiFragment length polymorphism methodGrowth factor useLogistical regression analysisLength polymorphism methodLogistic regression modelsInstitutional review boardNBS1 geneSystemic chemotherapyNeutrophil countChemotherapy administrationFactor support
1999
Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy
Pusztai L, Holmes F, Fraschini G, Hortobagyi G. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. Cancer Chemotherapy And Pharmacology 1999, 43: 86-91. PMID: 9923546, DOI: 10.1007/s002800050867.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerGranulocyte colony-stimulating factor supportColony-stimulating factor supportObjective response ratePhase II studyContinuous infusionBreast cancerII studyFactor supportSide effectsResponse rateMajor dose-limiting side effectDose-limiting side effectDiscontinuation of therapySecond-line chemotherapySecond-line regimensPhase II evaluationComplete tumor responseContinuous intravenous infusionMaximal cytotoxic effectLimited antitumor activityAsymptomatic cardiotoxicityPrevious therapyStable diseaseMetastatic disease